BRIEF published on 06/14/2024 at 22:50, 1 year 9 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase® Shareholders Theralase® Virtual Meeting AGSM Zoom Presentation
BRIEF published on 06/14/2024 at 22:50, 1 year 9 months ago Avis de rappel d'assemblée générale annuelle et extraordinaire des actionnaires de Theralase® Actionnaires Theralase® Réunion Virtuelle AGSM Présentation Zoom
PRESS RELEASE published on 06/14/2024 at 22:45, 1 year 9 months ago Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) Theralase Technologies Inc. provides a reminder for its Annual General and Special Meeting to be held on June 19th, 2024, with a virtual Zoom presentation including a Q&A session for shareholders Annual General Meeting Shareholders Theralase Technologies Inc. AGSM Virtual Zoom Presentation
BRIEF published on 06/12/2024 at 13:05, 1 year 9 months ago Rutherrin® Increases Efficacy of Chemotherapy Cancer Treatment Chemotherapy Rutherrin® Multidrug Resistance Theralase® Technologies
BRIEF published on 06/12/2024 at 13:05, 1 year 9 months ago Rutherrin® augmente l'efficacité de la chimiothérapie Traitement Du Cancer Chimiothérapie Rutherrin® Résistance Multidrogue Technologies Theralase®
PRESS RELEASE published on 06/12/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Increases Efficacy of Chemotherapy Theralase Technologies announces preclinical success of Rutherrin® in enhancing chemotherapy efficacy and reducing multidrug resistance in cancer cells Cancer Treatment Theralase Technologies Rutherrin® Multidrug Resistance Chemotherapy Efficacy
BRIEF published on 06/10/2024 at 13:05, 1 year 9 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Cancer Treatment Theralase Technologies Ruvidar(TM) BCG NMIBC
BRIEF published on 06/10/2024 at 13:05, 1 year 9 months ago Ruvidar(TM) améliore l'efficacité d'un médicament contre le cancer Traitement Du Cancer Technologies Théralase Ruvidar(TM) BCG NMIBC
PRESS RELEASE published on 06/10/2024 at 13:00, 1 year 9 months ago Ruvidar(TM) Enhances Efficacy of Cancer Drug Theralase® Technologies Inc. announces breakthrough in cancer research by developing RuBCG compound to enhance efficacy of bladder cancer treatment. Preclinical results show promising potential Theralase Technologies Inc. Cancer Research RuBCG Compound Bladder Cancer Treatment Preclinical Results
BRIEF published on 06/06/2024 at 13:05, 1 year 9 months ago Theralase Successfully Destroys Lung Cancer Preclinical Study Theralase Technologies Lung Cancer Rutherrin®
Published on 04/01/2026 at 08:05, 2 hours 25 minutes ago Tocvan Discovers New Gold-Silver Zone 1,600 Meters From Main Zone at South Block Gran Pilar; First Aggressive Step-Out Drilling Intersects Mineralization From Surface
Published on 04/01/2026 at 08:00, 2 hours 30 minutes ago Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 04/01/2026 at 04:06, 6 hours 24 minutes ago Jaguar Mining Reports Financial Results for the Fourth Quarter and Full Year 2025
Published on 04/01/2026 at 03:57, 6 hours 33 minutes ago NXT Energy Solutions Announces 2025 Year-End Results
Published on 04/01/2026 at 10:10, 19 minutes ago LITFINCON Announces European Debut: Global Litigation Finance Conference Series Comes to Amsterdam
Published on 04/01/2026 at 10:00, 29 minutes ago MS Industrie AG acquires real estate property in Trossingen and reports key figures for fiscal year 2025, along with a current business update and outlook for 2026
Published on 04/01/2026 at 09:05, 1 hour 24 minutes ago Solar Power to Go: Jackery Unveils SolarSaga 40 Air, the Next Generation of Compact Foldable Solar Panels
Published on 04/01/2026 at 09:05, 1 hour 24 minutes ago Rockwell Automation Announces ROKStudios Video Series Launches a New Season Exploring the Journey from Automation to Autonomy
Published on 04/01/2026 at 09:00, 1 hour 29 minutes ago Original-Research: LAIQON AG (von NuWays AG): BUY
Published on 04/01/2026 at 08:00, 2 hours 30 minutes ago Transfert du contrat de liquidité aupres de Natixis Oddo BHF
Published on 04/01/2026 at 08:00, 2 hours 30 minutes ago Résultats annuels 2025 - ANR par action en hausse de + 8,1 % à 97,10 € - Fonds propres consolidés : 740 M€
Published on 03/31/2026 at 20:08, 14 hours 21 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 15 hours 24 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 15 hours 24 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
